2019 American Transplant Congress
Outcomes of Induction Therapy with Bortezomib and High-Dose Intravenous Immunoglobulin for Kidney Transplantation with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies
Department of Urology, Ehime University, Toon, Japan
*Purpose: Preformed donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are known to increase the risk of antibody-mediated rejection (ABMR) and graft failure. However, effective methods…2019 American Transplant Congress
Decay Accelerating Factor (DAF) Regulates Germinal Center B-cell and Alloantibody Formation
*Purpose: High affinity IgG antibodies including alloantibodies result from germinal center (GC) reactions in which somatic hypermutation and positive selection cause affinity maturation. When we…2019 American Transplant Congress
Desensitization Protocols vs Kidney Paired Donation to Overcome AB0 Incompatibility and/or Donor Specific Antibodies in Living Donor Kidney Transplantation
Pancreas and Kidney Transplantation Center, University of Pisa, Pisa, Italy
*Purpose: International guidelines indicate Living Donor Kidney Transplantation (LDKT) as the best option for ESRD patients. Immunological barriers like AB0 incompatibility (AB0i) and donor specific…2019 American Transplant Congress
Epitop Matching Predicts Immunization in Kidney Transplant Recipients with Allograft Failure Leading to Worse Outcomes
*Purpose: The number of immunized patients on the waitlist is increasing worldwide. There is a lack of data about the impact of immunization after transplantation…2019 American Transplant Congress
Intra-Operative Kinetics of Anti-HLA Antibodies in Simultaneous Liver-Kidney Transplantation
Baylor College of Medicine, Houston, TX
*Purpose: In simultaneous liver-kidney transplantation (SLKT) in highly-sensitized patients, donor specific anti-HLA antibodies (DSA) can be present prior to transplant leading to positive crossmatch, yet…2019 American Transplant Congress
Angiotensin II Type 1 Receptor Antibodies Improve Risk Stratification for Kidney Allograft Outcomes at the Time of Transplantation
*Purpose: Current state-of-the-art pre-transplant risk stratification relies on the HLA system. Non-HLA agonistic angiotensin II type 1 receptor antibodies (AT1R-Ab) have been associated with allograft…2019 American Transplant Congress
Neutralization of Interlukin-6 by ALD518-P18 (Murine Clazakizumab) Attenuates Donor Specific Antibody Responses in a Mouse Model of Allogeneic Sensitization: A Report of Dosage Finding Study
Cedars-Sinai Med Ctr, Los Angeles, CA
*Purpose: Interleukin-6 (IL-6) is a proinflammatory cytokine involved in mediating both T-cell and B-cell responses in allograft rejection. In previous studies, we demonstrated that inhibition…2019 American Transplant Congress
Dual Targeting Desensitization with Carfilzomib Plus Lulizumab Significantly Prolongs Kidney Transplant Survival in Allosensitized Nonhuman Primates
Department of Surgery, Duke University Medical Center, Durham, NC
*Purpose: Sensitized patients are difficult to transplant due to pre-formed immunity against MHC antigens; thus, new strategies for desensitization are needed to improve outcomes in…2019 American Transplant Congress
Anti-HLA Antibodies Are Associated with Deterioration in Long-Term Renal Function Independently of Donor Specificity
*Purpose: Donor-specific antibodies (DSA) negatively impact graft survival, the clinical relevance of non-donor-specific anti-HLA antibodies (NDSA) is unclear. Hence, the purpose of our study is…2019 American Transplant Congress
Success in Lung Transplantation Outcomes after Receiving a Standardized Desensitization Therapy
*Purpose: With a goal to develop a safe, effective, and consistent approach to desensitization therapy using IVIg in lung transplant (LuT), we instituted a standard…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 19
- Next Page »